BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Gentilini A, Pastore M, Marra F, Raggi C. The Role of Stroma in Cholangiocarcinoma: The Intriguing Interplay between Fibroblastic Component, Immune Cell Subsets and Tumor Epithelium. Int J Mol Sci. 2018;19. [PMID: 30249019 DOI: 10.3390/ijms19102885] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 6.3] [Reference Citation Analysis]
Number Citing Articles
1 Yan C, Koda S, Wu J, Zhang BB, Yu Q, Netea MG, Tang RX, Zheng KY. Roles of Trained Immunity in the Pathogenesis of Cholangiopathies: A Therapeutic Target. Hepatology 2020;72:1838-50. [PMID: 32463941 DOI: 10.1002/hep.31395] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
2 Rompianesi G, Di Martino M, Gordon-Weeks A, Montalti R, Troisi R. Liquid biopsy in cholangiocarcinoma: Current status and future perspectives. World J Gastrointest Oncol 2021;13:332-50. [PMID: 34040697 DOI: 10.4251/wjgo.v13.i5.332] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 5] [Article Influence: 8.0] [Reference Citation Analysis]
3 Louis C, Edeline J, Coulouarn C. Targeting the tumor microenvironment in cholangiocarcinoma: implications for therapy. Expert Opin Ther Targets 2021;25:153-62. [PMID: 33502260 DOI: 10.1080/14728222.2021.1882998] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
4 Sirica AE, Strazzabosco M, Cadamuro M. Intrahepatic cholangiocarcinoma: Morpho-molecular pathology, tumor reactive microenvironment, and malignant progression. Adv Cancer Res 2021;149:321-87. [PMID: 33579427 DOI: 10.1016/bs.acr.2020.10.005] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
5 Wu HJ, Chu PY. Role of Cancer Stem Cells in Cholangiocarcinoma and Therapeutic Implications. Int J Mol Sci 2019;20:E4154. [PMID: 31450710 DOI: 10.3390/ijms20174154] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 7.3] [Reference Citation Analysis]
6 Fouassier L, Marzioni M, Afonso MB, Dooley S, Gaston K, Giannelli G, Rodrigues CMP, Lozano E, Mancarella S, Segatto O, Vaquero J, Marin JJG, Coulouarn C. Signalling networks in cholangiocarcinoma: Molecular pathogenesis, targeted therapies and drug resistance. Liver Int. 2019;39 Suppl 1:43-62. [PMID: 30903728 DOI: 10.1111/liv.14102] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 10.0] [Reference Citation Analysis]
7 Fabris L, Spirli C, Mertens J. Cell Interactions in Biliary Diseases: Clues from Pathophysiology and Repair Mechanisms to Foster Early Assessment. Int J Mol Sci 2019;20:E3961. [PMID: 31416247 DOI: 10.3390/ijms20163961] [Reference Citation Analysis]
8 Ebata N, Fujita M, Sasagawa S, Maejima K, Okawa Y, Hatanaka Y, Mitsuhashi T, Oosawa-Tatsuguchi A, Tanaka H, Miyano S, Nakamura T, Hirano S, Nakagawa H. Molecular Classification and Tumor Microenvironment Characterization of Gallbladder Cancer by Comprehensive Genomic and Transcriptomic Analysis. Cancers (Basel) 2021;13:733. [PMID: 33578820 DOI: 10.3390/cancers13040733] [Reference Citation Analysis]
9 Chatchawal P, Wongwattanakul M, Tippayawat P, Jearanaikoon N, Jumniansong A, Boonmars T, Jearanaikoon P, Wood BR. Monitoring the Progression of Liver Fluke-Induced Cholangiocarcinoma in a Hamster Model Using Synchrotron FTIR Microspectroscopy and Focal Plane Array Infrared Imaging. Anal Chem 2020;92:15361-9. [PMID: 33170647 DOI: 10.1021/acs.analchem.0c02656] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
10 Sato K, Glaser S, Alvaro D, Meng F, Francis H, Alpini G. Cholangiocarcinoma: novel therapeutic targets. Expert Opin Ther Targets. 2020;24:345-357. [PMID: 32077341 DOI: 10.1080/14728222.2020.1733528] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
11 Roy S, Glaser S, Chakraborty S. Inflammation and Progression of Cholangiocarcinoma: Role of Angiogenic and Lymphangiogenic Mechanisms. Front Med (Lausanne). 2019;6:293. [PMID: 31921870 DOI: 10.3389/fmed.2019.00293] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.7] [Reference Citation Analysis]
12 Fiste O, Ntanasis-Stathopoulos I, Gavriatopoulou M, Liontos M, Koutsoukos K, Dimopoulos MA, Zagouri F. The Emerging Role of Immunotherapy in Intrahepatic Cholangiocarcinoma. Vaccines (Basel) 2021;9:422. [PMID: 33922362 DOI: 10.3390/vaccines9050422] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Murtha-Lemekhova A, Fuchs J, Schulz E, Sterkenburg AS, Mayer P, Pfeiffenberger J, Hoffmann K. Scirrhous Hepatocellular Carcinoma: Systematic Review and Pooled Data Analysis of Clinical, Radiological, and Histopathological Features. J Hepatocell Carcinoma 2021;8:1269-79. [PMID: 34712626 DOI: 10.2147/JHC.S328198] [Reference Citation Analysis]
14 Kankeu Fonkoua LA, Serrano Uson Junior PL, Mody K, Mahipal A, Borad MJ, Roberts LR. Novel and emerging targets for cholangiocarcinoma progression: therapeutic implications. Expert Opin Ther Targets 2022. [PMID: 35034558 DOI: 10.1080/14728222.2022.2029412] [Reference Citation Analysis]
15 Fonkoua LAAK, Mahipal A. Research Progress of Biliary Tract Cancers. Cancers (Basel) 2021;13:919. [PMID: 33671644 DOI: 10.3390/cancers13040919] [Reference Citation Analysis]
16 Fabris L, Perugorria MJ, Mertens J, Björkström NK, Cramer T, Lleo A, Solinas A, Sänger H, Lukacs-Kornek V, Moncsek A, Siebenhüner A, Strazzabosco M. The tumour microenvironment and immune milieu of cholangiocarcinoma. Liver Int 2019;39 Suppl 1:63-78. [PMID: 30907492 DOI: 10.1111/liv.14098] [Cited by in Crossref: 31] [Cited by in F6Publishing: 26] [Article Influence: 15.5] [Reference Citation Analysis]
17 Caligiuri A, Pastore M, Lori G, Raggi C, Di Maira G, Marra F, Gentilini A. Role of Chemokines in the Biology of Cholangiocarcinoma. Cancers (Basel) 2020;12:E2215. [PMID: 32784743 DOI: 10.3390/cancers12082215] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
18 Boilève A, Hilmi M, Smolenschi C, Ducreux M, Hollebecque A, Malka D. Immunotherapy in Advanced Biliary Tract Cancers. Cancers (Basel) 2021;13:1569. [PMID: 33805461 DOI: 10.3390/cancers13071569] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
19 Mancarella S, Serino G, Coletta S, Armentano R, Dituri F, Ardito F, Ruzzenente A, Fabregat I, Giannelli G. The Tumor Microenvironment Drives Intrahepatic Cholangiocarcinoma Progression. IJMS 2022;23:4187. [DOI: 10.3390/ijms23084187] [Reference Citation Analysis]
20 Umemoto K, Togashi Y, Arai Y, Nakamura H, Takahashi S, Tanegashima T, Kato M, Nishikawa T, Sugiyama D, Kojima M, Gotohda N, Kuwata T, Ikeda M, Shibata T, Nishikawa H. The potential application of PD-1 blockade therapy for early-stage biliary tract cancer. Int Immunol 2020;32:273-81. [PMID: 31867666 DOI: 10.1093/intimm/dxz080] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
21 Bai M, Fu W, Su G, Cao J, Gao L, Huang C, Ma H, Zhang J, Yue P, Bai B, Lin Y, Meng W, Li X. The role of extracellular vesicles in cholangiocarcinoma. Cancer Cell Int 2020;20. [DOI: 10.1186/s12935-020-01526-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
22 Anichini G, Carrassa L, Stecca B, Marra F, Raggi C. The Role of the Hedgehog Pathway in Cholangiocarcinoma. Cancers (Basel) 2021;13:4774. [PMID: 34638259 DOI: 10.3390/cancers13194774] [Reference Citation Analysis]
23 Rimassa L, Personeni N, Aghemo A, Lleo A. The immune milieu of cholangiocarcinoma: From molecular pathogenesis to precision medicine. J Autoimmun 2019;100:17-26. [PMID: 30862450 DOI: 10.1016/j.jaut.2019.03.007] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 4.7] [Reference Citation Analysis]
24 Paillet J, Kroemer G, Pol JG. Immune contexture of cholangiocarcinoma. Curr Opin Gastroenterol 2020;36:70-6. [PMID: 31895228 DOI: 10.1097/MOG.0000000000000613] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
25 Hegde PS, Chen DS. Top 10 Challenges in Cancer Immunotherapy. Immunity 2020;52:17-35. [PMID: 31940268 DOI: 10.1016/j.immuni.2019.12.011] [Cited by in Crossref: 264] [Cited by in F6Publishing: 248] [Article Influence: 132.0] [Reference Citation Analysis]
26 Erlangga Z, Wolff K, Poth T, Peltzer A, Nahnsen S, Spielberg S, Timrott K, Woller N, Kühnel F, Manns MP, Saborowski A, Vogel A, Saborowski M. Potent Antitumor Activity of Liposomal Irinotecan in an Organoid- and CRISPR-Cas9-Based Murine Model of Gallbladder Cancer. Cancers (Basel) 2019;11:E1904. [PMID: 31795490 DOI: 10.3390/cancers11121904] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]